Study S001232

68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02560376
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Masking: NONE
Status: UNKNOWN
Enrollment: 100
Start: 2014-02
Primary completion: 2016-12
Lead sponsor: Peking Union Medical College Hospital
Conditions: Insulinoma; Nesidioblastosis
Interventions: DRUG:68Ga-NOTA-exendin-4
Results posted: FALSE
Secondary identifiers: NIH:ZIAEB000073

Registered primary outcomes

Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis of Insulinoma and Nesidioblastosis [1 year]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009621	Glucagon-like peptide-1 receptor PET/CT with 68Ga-exendin-4 for localizing insulinoma: a real-world, single-center study. Zhang H, European journal of nuclear medicine and molecular imaging	2025	Nonrandomized study	PMID 40310561 DOI	cites ClinicalTrials.gov:NCT02560376